SELENOP and diabetes mellitus: Administration of a neutralizing antibody against SeP to type 2 diabetes model KKAy mouse improved insulin sensitivity and glucose tolerance, suggesting that SeP is a biomarker of diabetes and a possible therapeutic target10.